Heart Failure, Left Sided Clinical Trial
Official title:
ContraBand™ Safety & Feasibility Study for Treatment of Heart Failure
The ContraBand™ device is intended for treatment of heart failure patients who remain symptomatic despite the use of optimally tolerated guideline directed medical therapy. ContraBand™ is a transcatheter constriction device which is implanted in the left and right branch pulmonary arteries, causing a local reduction in the internal diameters of these arteries, and resulting in an elevation in systolic right ventricular pressure. This may result in repositioning the interventricular septum to a more normal anatomical position, and supporting it with a "counter-pressure" during systole of the left ventricle. This study is a first-in-human, early feasibility, multi center, prospective, interventional, open-label, single-arm study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03774615 -
ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
|
Phase 4 | |
| Active, not recruiting |
NCT05350969 -
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
|
Phase 2 | |
| Terminated |
NCT03148847 -
Management of Cardiogenic Pulmonary Edema (RENAU-OAP)
|
||
| Completed |
NCT04397302 -
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
|